Get the Stockscreener App
15.80
5.33%
-0.89
After Hours:
15.82
0.02
+0.13%
Hims Hers Health Inc stock is traded at $15.80, with a volume of 31.62M.
It is down -5.33% in the last 24 hours and down -51.14% over the past month.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
See More
Previous Close:
$16.69
Open:
$16.52
24h Volume:
31.62M
Relative Volume:
1.51
Market Cap:
$3.60B
Revenue:
$1.78B
Net Income/Loss:
$164.40M
P/E Ratio:
22.90
EPS:
0.69
Net Cash Flow:
$236.51M
1W Performance:
-32.71%
1M Performance:
-51.14%
6M Performance:
-67.06%
1Y Performance:
-65.90%
1-Day Range:
$15.63
$16.96
1-Week Range:
$15.63
$23.62
52-Week Range:
$15.63
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Name
Hims Hers Health Inc
Sector
Phone
415-851-0195
Address
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
15.80 | 3.80B | 1.78B | 164.40M | 236.51M | 0.69 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.37 | 57.75B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.64 | 56.70B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.92 | 39.96B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
476.13 | 20.49B | 3.13B | 1.27B | 1.12B | 26.39 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-26 | Initiated | Evercore ISI | In-line |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-21-25 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-23-25 | Downgrade | Needham | Buy → Hold |
| Jun-04-25 | Reiterated | Needham | Buy |
| Apr-29-25 | Downgrade | TD Cowen | Buy → Hold |
| Feb-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-25 | Downgrade | Citigroup | Neutral → Sell |
| Jan-07-25 | Initiated | BTIG Research | Buy |
| Dec-17-24 | Initiated | Morgan Stanley | Overweight |
| Nov-14-24 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-22-24 | Initiated | Needham | Buy |
| Aug-09-24 | Downgrade | Imperial Capital | Outperform → In-line |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Apr-16-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-10-24 | Initiated | Canaccord Genuity | Buy |
| Feb-28-24 | Upgrade | Imperial Capital | In-line → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-07-23 | Initiated | Imperial Capital | In-line |
| Jul-28-23 | Initiated | TD Cowen | Outperform |
| Apr-11-23 | Initiated | Robert W. Baird | Neutral |
| Feb-09-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-08-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-17-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-07-22 | Initiated | Truist | Hold |
| Jul-15-22 | Initiated | SVB Leerink | Underperform |
| Apr-14-22 | Initiated | Guggenheim | Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | Deutsche Bank | Hold |
| Dec-02-21 | Initiated | Jefferies | Hold |
| Nov-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-06-21 | Initiated | BofA Securities | Neutral |
| May-20-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-21-21 | Initiated | Truist | Hold |
| Mar-09-21 | Initiated | Credit Suisse | Neutral |
| Mar-02-21 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-21 | Initiated | Citigroup | Neutral |
| Feb-12-21 | Initiated | Piper Sandler | Neutral |
| Feb-08-21 | Initiated | Tigress Financial | Buy |
View All
Hims Hers Health Inc Stock (HIMS) Latest News
Novo Nordisk Plans Wegovy Vial Launch To Counter Eli Lilly, Target Broader Obesity Market - Benzinga
Hims & Hers Strengthens Integrated Personalized Digital Care Platform - The Globe and Mail
Mixed options sentiment in Hims and Hers Health with shares down 2.18% - Yahoo Finance
Him & Hers Health Stock Forecast 2026–2030 | Future Outlook - Capital.com
Novo Nordisk CEO Sees Opportunity For 15 Million New Patients As Medicare Covers Obesity Drugs - Benzinga
Hims & Hers Pulls Wegovy Pill Dupe After FDA Threats — Novo Nordisk Files Patent Lawsuit Anyway - Everyday Health
Novo to Follow Lilly and Sell Obesity Shot Wegovy in Vials - Bloomberg.com
Hims & Hers Faces Legal and Regulatory Headwinds, Stock Plummets - StocksToTrade
HIMS Stock Plunges 8 Straight Days: Is The GLP-1 Fallout Already Priced In? - Stocktwits
HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell? - The Globe and Mail
Hims & Hers: Does Big Pharma Always Win? (Rating Downgrade) (NYSE:HIMS) - Seeking Alpha
HIMS Selloff Creates De-Risked Entry (NYSE:HIMS) - Seeking Alpha
Hims & Hers Halts Compounded Semaglutide Pill Offering After FDA's Crackdown Warning - AOL.com
Pharmaceutical industry spends more on ads in the US despite stricter FDA guidelines - medwatch.com
The Price Is Right For Hims & Hers Health, Inc. (NYSE:HIMS) Even After Diving 46% - simplywall.st
Novo’s GLP-1 Patent Suit Against Hims Takes Aim at Compounding - Bloomberg Law News
Hims is in the crosshairs. Is a crackdown coming for compounding? - statnews.com
Deutsche Bank Maintains Hold on HIMS (Hims & Hers) Feb 10, 2026 - Meyka
'Health risk': Novo Nordisk sues Hims & Hers over cheaper version of Ozempic, Wegovy fat loss pills - MSN
Meet The Attys For Novo Nordisk In Hims & Hers GLP-1 Row - Law360
Legal pressures mount for Hims & Hers over GLP-1 sales - The Hill
Novo Nordisk Takes On Hims Over Copycat GLP-1 Pill - Law360
Stocks making big moves yesterday: Shopify, Snowflake, Ryan Specialty, Merchants Bancorp, and Hims & Hers Health - The Globe and Mail
Novo Nordisk Files Patent Lawsuit Against Hims & Hers Over Compounded Semaglutide Products - Law Commentary
Fight over GLP-1 alternatives escalates as Novo Nordisk sues Hims & Hers - Axios
Novo Nordisk sues Hims & Hers over ‘knock-off Wegovy’ - The Hill
Decoding Hims & Hers Health's Options Activity: What's the Big Picture? - Benzinga
Palmetto Grain Brokerage - Palmetto Grain Brokerage
As Hims & Hers Gets Hit With Major Wegovy Loss, Should You Buy the Dip in Deeply Oversold HIMS Stock? - Yahoo Finance
Hims & Hers Health: The GLP-1 Trade Just Got Real (Rating Downgrade) (NYSE:HIMS) - Seeking Alpha
The Vertical Integration of Wellness: A Deep Dive into Hims & Hers Health (HIMS) - FinancialContent
Deutsche Bank Cuts Price Target on Hims & Hers Health to $31 From $42, Keeps Hold Rating - marketscreener.com
Hims & Hers Health Stock (HIMS) Opinions on Novo Nordisk Lawsuit - Quiver Quantitative
Novo Nordisk, maker of Ozempic, sues over weight loss drug copycats - NewsNation
Hims & Hers says Novo Nordisk lawsuit ‘blatant attack’ on millions of Americans - Yahoo Finance
Hims & Hers Health, Inc. $HIMS Shares Purchased by Candriam S.C.A. - MarketBeat
Hims & Hers stock drops again premarket as $49 weight-loss pill reversal fuels legal, FDA scrutiny - TechStock²
Hims And Hers Retreats On GLP1 Pills As Legal And Regulatory Risks Grow - Yahoo Finance
Novo Nordisk Rallies 3.6% as Hims & Hers Pulls Compounded Semaglutide - Yahoo Finance
The Knockoff GLP-1 Market Is Still the Wild West - Bloomberg.com
Hims & Hers retreats from compounded GLP-1 pill - Axios
Novo Nordisk opens new front with patent suit over Hims’ Wegovy copies - Yahoo Finance
Why Hims Stock Slid 40% In A Month? - Forbes
Hims built a boundary-pushing health business. Now the legal risks are catching up. - Sherwood News
Hims and Novo Nordisk: Compounded Oral Semaglutide Pulled After Legal Challenge and HHS Pressure - Morningstar Canada
Hims & Hers Stock (-16%): GLP-1 Ambitions Crushed by Lawsuit & FDA - Trefis
HIMS Stock Plunges as Novo Lawsuit Triggers Analyst Price Target Cuts - TipRanks
Novo Nordisk Launches Suit to Knock Out Hims & Hers’ Weight Loss Knockoffs - Yahoo Finance
Hims Pulls Cheaper Wegovy Pill After Federal Scrutiny - Optometry Advisor
Stocks to Watch Monday Recap: Novo Nordisk, Hims & Hers, Apollo - The Wall Street Journal
Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit - Yahoo Finance
Hims Hers Health Inc Stock (HIMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.70%
10.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):